FMS 📈 Fresenius Medical Care - Overview

Exchange: NYSE • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US3580291066

FMS: Dialyzers, Machines, Solutions, Pharmaceuticals, Equipment, Supplies, Services

Fresenius Medical Care AG is a leading global healthcare company that specializes in providing dialysis and related services to individuals with renal diseases. With a strong presence in Germany, North America, and internationally, the company operates a vast network of outpatient dialysis clinics, offering comprehensive treatment and laboratory services to patients.

In addition to its clinic-based services, Fresenius Medical Care AG provides a range of support services, including clinical monitoring, follow-up assistance, and delivery of essential supplies to patients' homes. The company also partners with hospitals in the United States to provide dialysis services to hospitalized patients with end-stage renal disease (ESRD) and acute kidney failure.

The company's product portfolio is extensive, featuring a wide range of healthcare products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, and solutions. Fresenius Medical Care AG also develops and distributes systems for water treatment, acute cardiopulmonary and apheresis products, and renal pharmaceuticals. Furthermore, the company offers vascular, cardiovascular, endovascular specialty, and physician nephrology and cardiology services, as well as renal medications and supplies to patients at home or in dialysis clinics.

Fresenius Medical Care AG's products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, as well as through a network of local sales forces, independent distributors, dealers, and sales agents. With a strong commitment to innovation and patient care, the company has established itself as a leader in the global healthcare industry since its incorporation in 1996. Headquartered in Bad Homburg, Germany, Fresenius Medical Care AG continues to drive advancements in renal care and improve the lives of patients worldwide.

Additional Sources for FMS Stock

FMS Stock Overview

Market Cap in USD 13,192m
Sector Healthcare
Industry Medical Care Facilities
GiC Industry Health Care Providers & Services
TER 0.00%
IPO / Inception 1996-09-19

FMS Stock Ratings

Growth 5y -35.2%
Fundamental 35.7%
Dividend 35.2%
Rel. Performance Sector -0.01
Analysts 3/5
Fair Price Momentum 23.54 USD
Fair Price DCF 81.17 USD

FMS Dividends

Dividend Yield 12m 2.72%
Yield on Cost 5y 2.00%
Annual Growth 5y -1.16%
Payout Consistency 96.77%

FMS Growth Ratios

Growth Correlation 3m 58.2%
Growth Correlation 12m 39.1%
Growth Correlation 5y -77.7%
CAGR 5y -5.97%
CAGR/Mean DD 5y -0.18
Sharpe Ratio 12m 0.54
Alpha -5.17
Beta 0.63
Volatility 33.35%
Current Volume 257.9k
Average Volume 20d 244.4k
What is the price of FMS stocks?
As of December 04, 2024, the stock is trading at USD 23.33 with a total of 257,862 shares traded.
Over the past week, the price has changed by +5.52%, over one month by +16.36%, over three months by +21.51% and over the past year by +13.95%.
Is Fresenius Medical Care a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Fresenius Medical Care (NYSE:FMS) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 35.72 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FMS as of December 2024 is 23.54. This means that FMS is currently overvalued and has a potential downside of 0.9%.
Is FMS a buy, sell or hold?
Fresenius Medical Care has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold FMS.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 1
  • Strong Sell: 1
What are the forecast for FMS stock price target?
According to ValueRays Forecast Model, FMS Fresenius Medical Care will be worth about 25.4 in December 2025. The stock is currently trading at 23.33. This means that the stock has a potential upside of +8.96%.
Issuer Forecast Upside
Wallstreet Target Price 21.2 -9.3%
Analysts Target Price 20.1 -13.9%
ValueRay Target Price 25.4 9%